Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French men

Abstract Introduction The Memorial Anxiety Scale for Prostate Cancer (MAX-PC, 18 items) was developed to assess anxiety in prostate cancer patients. In the absence of a French version of this scale, we adapted the original English scale and evaluated its psychometric properties in a sample of French...

Full description

Bibliographic Details
Main Authors: Rajae Touzani, Julien Mancini, Jaïs Troïan, Anne-Déborah Bouhnik, Olivier Cussenot, Gwenaelle Gravis, Patricia Marino
Format: Article
Language:English
Published: SpringerOpen 2019-09-01
Series:Journal of Patient-Reported Outcomes
Subjects:
Online Access:http://link.springer.com/article/10.1186/s41687-019-0150-1
id doaj-6c13a7032c404c3d866ea8fdcaec04ea
record_format Article
spelling doaj-6c13a7032c404c3d866ea8fdcaec04ea2020-11-25T02:53:02ZengSpringerOpenJournal of Patient-Reported Outcomes2509-80202019-09-01311810.1186/s41687-019-0150-1Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French menRajae Touzani0Julien Mancini1Jaïs Troïan2Anne-Déborah Bouhnik3Olivier Cussenot4Gwenaelle Gravis5Patricia Marino6Institut Paoli-CalmettesAix Marseille Univ., APHM, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, Hop Timone, BioSTIC, Biostatistique et Technologies de l’Information et de la CommunicationAix-Marseille Univ., Laboratoire de Psychologie Sociale (LPSEA849)Aix Marseille Univ., INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information MédicaleAPHP, Hôpitaux Universitaires Est Parisien, Service Urologie, Sorbonne UniversitéMedical Oncology, Institut Paoli Calmettes, Centre de Recherche en Cancérologie de Marseille, Aix Marseille UniversitéInstitut Paoli-CalmettesAbstract Introduction The Memorial Anxiety Scale for Prostate Cancer (MAX-PC, 18 items) was developed to assess anxiety in prostate cancer patients. In the absence of a French version of this scale, we adapted the original English scale and evaluated its psychometric properties in a sample of French men diagnosed with prostate cancer in the previous 12 months. Methods The MAX-PC was translated from English to French and distributed online by two non-profit organizations (Seintinelles and ANAMACaP). The French questionnaire, which also included the Hospital Anxiety and Depression Scale (HADS) and a measure of health-related quality of life (SF12), was intended for adults diagnosed with prostate cancer in the previous 12 months. Factor structure was assessed using exploratory factor analysis (EFA) on data from 56.2% of the sample (n = 104, Seintinelles subsample) and confirmed using confirmatory factor analysis (CFA) on data from the rest of the sample (n = 81, ANAMACaP subsample). The reliability of the scale was measured using Cronbach’s alpha coefficient. Construct validity was assessed by calculating the correlation of the MAX-PC total score and subscale scores with the HADS total score and subscale scores and with the SF12 total score and subscale scores. Results Of the 185 respondents, 168 (90.8%) had complete data on all MAX-PC items. The average age of participants was 65.1 years (SD: 7.7). The three-factor structure defined in the original validation study was very similar in EFA and then confirmed by CFA. The MAX-PC showed good reliability, as Cronbach’s alpha coefficients for the scale and for its three subscales were 0.92, 0.90, 0.68, and 0.87, respectively. It also showed good construct validity. As expected, the MAX-PC total score was positively correlated with the HADS-Anxiety subscale score (r = 0.68, p < 0.001) and negatively correlated with the SF12-MCS subscale score (r = − 0.35, p < 0.001). Conclusion The French version of the MAX-PC shows adequate psychometric properties among French men with prostate cancer. This scale may be used in future studies and in routine clinical care to help health care providers identify patients who need psychological support due to prostate-cancer related anxiety.http://link.springer.com/article/10.1186/s41687-019-0150-1MAX-PCProstate cancerValidationFrench men
collection DOAJ
language English
format Article
sources DOAJ
author Rajae Touzani
Julien Mancini
Jaïs Troïan
Anne-Déborah Bouhnik
Olivier Cussenot
Gwenaelle Gravis
Patricia Marino
spellingShingle Rajae Touzani
Julien Mancini
Jaïs Troïan
Anne-Déborah Bouhnik
Olivier Cussenot
Gwenaelle Gravis
Patricia Marino
Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French men
Journal of Patient-Reported Outcomes
MAX-PC
Prostate cancer
Validation
French men
author_facet Rajae Touzani
Julien Mancini
Jaïs Troïan
Anne-Déborah Bouhnik
Olivier Cussenot
Gwenaelle Gravis
Patricia Marino
author_sort Rajae Touzani
title Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French men
title_short Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French men
title_full Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French men
title_fullStr Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French men
title_full_unstemmed Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French men
title_sort adaptation and validation of the memorial anxiety scale for prostate cancer (max-pc) in a sample of french men
publisher SpringerOpen
series Journal of Patient-Reported Outcomes
issn 2509-8020
publishDate 2019-09-01
description Abstract Introduction The Memorial Anxiety Scale for Prostate Cancer (MAX-PC, 18 items) was developed to assess anxiety in prostate cancer patients. In the absence of a French version of this scale, we adapted the original English scale and evaluated its psychometric properties in a sample of French men diagnosed with prostate cancer in the previous 12 months. Methods The MAX-PC was translated from English to French and distributed online by two non-profit organizations (Seintinelles and ANAMACaP). The French questionnaire, which also included the Hospital Anxiety and Depression Scale (HADS) and a measure of health-related quality of life (SF12), was intended for adults diagnosed with prostate cancer in the previous 12 months. Factor structure was assessed using exploratory factor analysis (EFA) on data from 56.2% of the sample (n = 104, Seintinelles subsample) and confirmed using confirmatory factor analysis (CFA) on data from the rest of the sample (n = 81, ANAMACaP subsample). The reliability of the scale was measured using Cronbach’s alpha coefficient. Construct validity was assessed by calculating the correlation of the MAX-PC total score and subscale scores with the HADS total score and subscale scores and with the SF12 total score and subscale scores. Results Of the 185 respondents, 168 (90.8%) had complete data on all MAX-PC items. The average age of participants was 65.1 years (SD: 7.7). The three-factor structure defined in the original validation study was very similar in EFA and then confirmed by CFA. The MAX-PC showed good reliability, as Cronbach’s alpha coefficients for the scale and for its three subscales were 0.92, 0.90, 0.68, and 0.87, respectively. It also showed good construct validity. As expected, the MAX-PC total score was positively correlated with the HADS-Anxiety subscale score (r = 0.68, p < 0.001) and negatively correlated with the SF12-MCS subscale score (r = − 0.35, p < 0.001). Conclusion The French version of the MAX-PC shows adequate psychometric properties among French men with prostate cancer. This scale may be used in future studies and in routine clinical care to help health care providers identify patients who need psychological support due to prostate-cancer related anxiety.
topic MAX-PC
Prostate cancer
Validation
French men
url http://link.springer.com/article/10.1186/s41687-019-0150-1
work_keys_str_mv AT rajaetouzani adaptationandvalidationofthememorialanxietyscaleforprostatecancermaxpcinasampleoffrenchmen
AT julienmancini adaptationandvalidationofthememorialanxietyscaleforprostatecancermaxpcinasampleoffrenchmen
AT jaistroian adaptationandvalidationofthememorialanxietyscaleforprostatecancermaxpcinasampleoffrenchmen
AT annedeborahbouhnik adaptationandvalidationofthememorialanxietyscaleforprostatecancermaxpcinasampleoffrenchmen
AT oliviercussenot adaptationandvalidationofthememorialanxietyscaleforprostatecancermaxpcinasampleoffrenchmen
AT gwenaellegravis adaptationandvalidationofthememorialanxietyscaleforprostatecancermaxpcinasampleoffrenchmen
AT patriciamarino adaptationandvalidationofthememorialanxietyscaleforprostatecancermaxpcinasampleoffrenchmen
_version_ 1724726974914494464